RxDoctor Payments DataLook up a doctor →

Alicia Cabrera, MD

Neurology · Altamonte Springs, FLNPI 1770789000

Payments from drug & device makers

$9,307,695in general payments, 2019–2025

Across 1,719 payments — averaging $5414.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$5M
  • Eli Lilly$1.2M
  • E.r. Squibb & Sons, L.L.C.$1M
  • Sanofi$738K
  • Genentech, Inc.$672K
  • UCB SA$310K
  • plus $460K from 54 others
$15,835in research payments, 2019–2025

Across 14 payments — averaging $1131.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$14K
  • Sanofi US Services Inc.$875
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$411
  • Novartis Pharma AG$95

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis93$4,959,803
Eli Lilly17$1,161,856
E.r. Squibb & Sons, L.L.C.9$1,004,865
Sanofi54$738,312
Genentech, Inc.37$672,442
UCB SA2$310,396
EMD Serono, Inc.89$151,387
Ares Trading SA68$118,998
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)30$84,385
Otsuka Pharmaceutical Development & Commercialization, Inc.4$53,472
Biogen92$23,462
AbbVie(2 entities)265$7,089
Neurocrine Biosciences, Inc.73$1,483
Teva Pharmaceuticals USA, Inc.82$1,418
Acadia Pharmaceuticals Inc75$1,359
Supernus Pharmaceuticals, Inc.59$1,302
Genentech USA, Inc.44$1,112
Pfizer66$1,080
Amgen(2 entities)34$1,046
Jazz Pharmaceuticals Inc.13$970
Bristol Myers Squibb44$889
TG Therapeutics, Inc.9$837
AstraZeneca31$767
UCB, Inc.22$731
Eisai Inc.37$674
Lilly USA, LLC34$673
Biohaven Pharmaceuticals, Inc.33$634
Upsher-smith Laboratories LLC23$571
Biohaven Pharmaceutical Holding Company Ltd.31$548
Johnson & Johnson(2 entities)13$516
Amneal Pharmaceuticals LLC27$498
Acorda Therapeutics, Inc15$316
Banner Life Sciences, LLC13$298
Lundbeck LLC14$264
Mallinckrodt Hospital Products Inc.13$227
Corium, LLC12$210
MDD US Operations, LLC17$201
Takeda Pharmaceuticals U.S.A., Inc.7$175
Adamas Pharmaceuticals, Inc.12$175
Sunovion Pharmaceuticals Inc.7$162
Grifols USA, LLC9$152
Abbott1$151
Scilex Pharmaceuticals Inc.9$133
Bayer1$124
Livanova USA, Inc.4$100
SK Life Science, Inc.4$96
EMD Serono Research & Development Institute, Inc.1$92
Kyowa Kirin, Inc.4$84
Otsuka America Pharmaceutical, Inc.4$83
GE HealthCare4$82
Argenx US, Inc.5$81
Currax Pharmaceuticals LLC6$76
Zyla Life Sciences, Inc.5$73
Mallinckrodt Enterprises LLC3$69
Axsome Therapeutics, Inc.3$68
Avanir Pharmaceuticals, Inc.4$63
Arbor Pharmaceuticals, Inc.4$56
CSL Behring3$53
Cycle Pharmaceuticals Inc2$47
Avion Pharmaceuticals3$45

How this compares

$9,307,695 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$1,089,297
Medicare patients
631
Services billed
28,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Altamonte Springs

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →